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Abstract 
Biochemical studies of eukaryotic proteins are often constrained by low availability of these typically 
large, multicomponent protein complexes in pure form. Escherichia coli is a commonly used host for large-scale 
protein production; however, its utility for eukaryotic protein production is limited because of problems 
associated with transcription, translation, and proper folding of proteins. Here we describe the development 
and testing of pLANT, a vector that addresses many of these problems simultaneously. The pLANT vector 
contains a T7 promoter-controlled expression unit, a p15A origin of replication, and genes for rare transfer RNAs 
and kanamycin resistance. Thus, the pLANT vector can be used in combination with the pET vector to coexpress 
multiple proteins in E. coli. Using this approach, we have successfully produced high-milligram quantities of two 
different Saccharomyces cerevisiae complexes in E. coli: the heterodimeric Msh2–Msh6 mismatch repair protein 
(248 kDa) and the five-subunit replication factor C clamp loader (250 kDa). Quantitative analyses indicate that 
these proteins are fully active, affirming the utility of pLANT+pET-based production of eukaryotic proteins in E. 
coli for in vitro studies of their structure and function. 
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Many key metabolic and regulatory processes of the cell are driven by the action of large protein assemblies. 
In Escherichia coli DNA metabolism, for example, the 10-subunit DNA polymerase III holoenzyme catalyzes DNA 
replication and is required for both recombination and repair [1]. Often, the protein machinery of eukaryotic 
organisms comprises even more intricate multicomponent versions of prokaryotic counterparts. For example, in 
the bacterial DNA mismatch repair system, a single MutS polypeptide functions as a homodimer to recognize 
errors in DNA and signal initiation of repair, whereas eukaryotes contain several MutS homologues (Msh)1 that 
function as heterodimers (e.g., Saccharomyces cerevisiae and human Msh2–Msh6 and Msh2–Msh3) [2], [3]. 
Detailed biochemical and biophysical studies require large-scale production of these protein complexes, which is 
usually accomplished by overexpression and purification of individual subunits from a host organism such as E. 
coli, followed by reconstitution of the complexes in vitro. In some cases, this method has yielded protein 
complexes in sufficient quantities for crystal structure determination (e.g., E. coli γ complex clamp loader [4] and 
the nucleosome core particle [5], among others). Quite often, however, in vitro reconstitution yields can be very 
low because one or more of the individual subunits are misfolded or are otherwise unstable/insoluble in the 
absence of their interacting partners. In fact, overproduction of heterologous (e.g., eukaryotic) proteins in E. 
coli—particularly components of multiprotein complexes—often results in aggregation and formation of 
inclusion bodies [6]. Another challenge for large-scale eukaryotic protein complex production is the low 
expression level of these proteins in E. coli, the most convenient and commonly used host organism. This 
problem may be largely due to differential codon usage in prokaryotes and eukaryotes (codon bias). For 
example, the AGA and AGG arginine codons routinely found in S. cerevisiae genes are rarely used in E. coli; 
therefore, the E. coli translational machinery is not equipped to handle such genes [7], [8]. 
Problems related to multiprotein complex solubility and stability can often be solved by coexpression of the 
individual components in vivo[9]. This strategy has been used successfully to produce a wide variety of protein 
complexes, including nuclear receptor proteins [10], immunoglobulin Fv fragment [11], Schizosaccharomyces 
pombe RPA single-stranded DNA binding protein [12], human RPA [13], and the VHL–elonginC–elonginB 
complex [14]. Moreover, there is an increase in production efficiency, as the entire protein complex is purified at 
one time rather than in a piecemeal fashion. The component proteins can be coexpressed from a single plasmid 
vector carrying several genes in monocistronic or polycistronic units. Depending on the size of the protein 
complex, however, this plasmid may well be excessively large and difficult to prepare and manipulate. An 
alternate strategy is to utilize multiple vectors with compatible origins of replication and different resistance 
markers to coexpress the proteins. 
In this report, we describe the development of pLANT, an overexpression vector that is compatible with the pET 
vector system for co-expression of proteins in E. coli. In addition, we have prepared an advanced version of the 
pLANT vector that contains genes for tRNAs rarely used in E. coli but essential for good expression of many S. 
cerevisiae and other eukaryotic genes [8], [15], [16]. The pLANT+pET combination was tested for expression in E. 
coli of two large eukaryotic protein complexes, the S. cerevisiae Msh2–Msh6 dimer and the 5-subunit replication 
factor C (RFC) clamp loader. We demonstrate that the single subunits of these complexes are insoluble when 
expressed individually; however, when all the subunits are expressed together (with the help of appropriate 
tRNAs), tens of milligrams of fully active Msh2–Msh6 and RFC can be purified from E. coli with ease. Finally, we 
have performed active site titrations with their respective substrates to demonstrate that the pure complexes 
are fully active. 
Materials and methods 
pLANT vector design and development 
pLANT vectors were constructed in a multistep procedure initiated by replacement of the ColE1 replication 
origin of pET-9c (Novagen [17]) with the p15A replication origin. A 3.5-kb AlwNI/XmnI fragment of pET-9c 
(excluding the replication origin but containing the T7 promoter-mediated expression unit 
and kanamycin resistance gene) was treated with Klenow fragment and alkaline phosphatase (New England 
Biolabs) to form a blunt end and then ligated to the 0.88-kb XmnI/ClaI blunt end fragment of pACYC184 (New 
England Biolabs) containing the p15A origin to yield the 4.4-kb pLANT-1. These manipulations, and others to 
follow below, were performed as described [18]. Next, pLANT-2 was formed by incorporating the T7 expression 
unit from pET-11a (Novagen) into pLANT-1. Briefly, the 3.8-kb BglII/EcoRI fragment from pLANT-1 was ligated to 
a 0.47-kb BglII/EcoRI fragment from pET-11a. The resulting pLANT-2 vector offers the standard restriction 
sites NdeI/BamHI for subcloning genes (as does pLANT-1) and extra control of the T7 promoter via the 
overlapping lac operator. The pLANT-3 vector was formed by incorporating the T7 expression unit from pET-16b 
into pLANT-1. In this case, the 0.5-kb BglII/EcoRI fragment from pET-16b was ligated to the 3.8-kb BglII/EcoRI 
fragment of pLANT-1. This vector allows production of proteins with a His-tag (if the NdeI site is used; no His tag 
if the NcoI site is used). Both pLANT-2 and pLANT-3 vectors were modified further by introduction of argU (for 
AGA and AGG codons), ileY (for AUA), and leuW (for the CUA codon) tRNA genes between the HindIII/EcoRI sites. 
The resulting overexpression vectors, pLANT-2/RIL and pLANT-3/RIL, carry a p15A replication origin, a 
T7lac promoter followed by the efficient ribosome binding site of T7 gene 1 protein, a gene insertion site 
(at NdeI or NcoI, which provide the translation start codon), a T7 transcription terminator, a kanamycin 
resistance gene, and tRNA genes to compensate for codon bias. 
Cloning of S. cerevisiae genes into pLANT or pET vectors 
Msh2 and Msh6 genes were amplified from S. cerevisiae genomic DNA using oligonucleotide primers that 
introduced an NdeI site at the initiating methionine and placed a BamHI site 70 nucleotides past the stop codon. 
The PCR products for Msh2 and Msh6 were ligated individually into the NdeI/BamHI sites of pET-11a and pLANT-
2/RIL vectors, respectively. 
A pET plasmid encoding the RFC2, 3, and 4 subunits was prepared by first amplifying the RFC2, 3, and 4 genes 
from S. cerevisiae genomic DNA and cloning them individually into the NdeI/BamHI sites of pET-11a (RFC3) or 
the NcoI/BamHI sites in pET-16b (RFC2 and 4). To prepare plasmids for coexpression of these RFC proteins in E. 
coli, RFC2, RFC3, and RFC4 genes were combined into a single pET-11a vector. A BglII/ClaI fragment of pET(11a)–
RFC3 containing the gene and T7 promotor was blunted and inserted into pET(11a)–RFC4 (cut with AvaI, 
blunted, and phosphatased). Next, pET(11a)–RFC[3+4] was cut with SphI, blunted, and phosphatased; then 
a BglII/HindIII fragment of pET(11a)–RFC2, containing the gene and T7 promotor, was blunted and ligated to the 
linearized pET(11a)–RFC[3+4]. The resulting 9.6-kb pET(11a)–RFC[2+3+4] plasmid contains three RFC subunit 
genes, each in individual T7 expression units. The RFC2, 3, and 4 genes were sequenced to ensure that no errors 
were introduced during the PCR amplification. 
Next, the genes encoding RFC1 and RFC5 were amplified from S. cerevisiae genomic DNA and inserted 
individually into the NdeI/BamHI sites of pLANT-2/RIL (RFC5) or the NcoI/BamHI sites of pET-16b (RFC1s). A 
modified version of RFC5 protein—RFC5HK—was prepared by inserting DNA encoding the amino acid 
sequence MGLRRASVHHHHHHSSGHIEGRH (which contains a Kinase tag for 32P labeling with cAMP-dependent 
protein kinase and a six-histidine tag) into the NdeI site of pLANT-2/RIL–RFC5 to yield pLANT-2/RIL–RFC5HK. To 
construct the RFC[1+5]–pLANT vector, an SgrAI/ClaI fragment of pET(11a)-RFC1 was blunted and inserted into 
pLANT-2/RIL–RFC5HK (cut with EcoRV and phosphatased) to yield pLANT-2/RIL–RFC[1+5HK]. To produce a 
truncated version of RFC1 protein, RFC1s, the gene was truncated by PCR such that 282 amino acids from the N 
terminus were deleted, and the glycine at position 283 was changed to methionine. The truncated RFC1s gene 
fragment was cut using NdeI and BamHI and inserted into NdeI/BamHI sites of pET-11a to yield pET(11a)–RFC1s. 
An SgrAI/ClaI fragment of pET(11a)–RFC1s was blunted and inserted into pLANT-2/RIL–RFC5 (cut with EcoRV and 
phosphatased) to yield pLANT-2/RIL–RFC[1s+5]. The RFC1s and RFC5 genes were sequenced to ensure that no 
errors were incurred during PCR amplification. These pLANT-based plasmids were used in combination with 
pET(11a)–RFC[2+3+4] to produce modified RFC complexes. 
Overexpression and purification of S. cerevisiae proteins from E. coli 
For overproduction of Msh2–Msh6 protein complex, the pLANT-2/RIL–Msh6 and pET(11a)–Msh2 plasmids were 
cotransformed into BLR(DE3) cells (Novagen) and selected for resistance to both ampicillin and kanamycin; 0.5–
1 μg of each plasmid is required for efficient cotransformation. A fresh transformant was grown in 16 liters of LB 
media containing ampicillin (100 μg/ml) and kanamycin (50 μg/ml) at 37 °C to OD600 0.6 and induced with 
0.5 mM isopropyl-β-d-thiogalactoside for 3 h. All further steps were performed at 4 °C. The cells were harvested 
by centrifugation and then resuspended in 300 ml of Buffer A (25 mM Tris–HCl (pH 8.0), 1 mM EDTA, 5% 
glycerol, 1 mM phenylmethylsulfonyl fluoride) containing 1 M NaCl. The cells were lysed by treatment 
with lysozyme (0.4 mg/ml), three freeze–thaw cycles (liquid N2 and 37 °C), and, finally, treatment in a Dounce 
homogenizer. The cell lysate was clarified by centrifugation and dialyzed overnight against Buffer A. Msh2–
Msh6 protein complex was purified by sequential ion-exchange chromatography over an SP-Sepharose column 
(Buffer A; 20 ml bed volume; 200 ml gradient of 150–400 mM NaCl), Affi-Gel heparin column (20 ml bed volume; 
200 ml gradient of 250–500 mM NaCl in Buffer B (20 mM potassium phosphate (pH 7.2), 0.5 mM EDTA, 5% 
glycerol)), and Q-Sepharose column (5 ml bed volume; 60 ml gradient of 200–600 mM NaCl in Buffer A). 
Following the Q-Sepharose column, the protein was dialyzed against Buffer A to a conductivity equal to 100 mM 
NaCl and concentrated by centrifugation through a centricon-10 (Millipore) to a concentration of approximately 
2 mg/ml. The final yield is 1–1.2 mg of Msh2–Msh6 complex per liter of cell culture. The final preparation 
of Msh2–Msh6 complex is greater than 95% pure. The Msh2–Msh6 concentration was measured by Bradford 
assay and by absorbance at 280 nm in 6 M guanidinium hydrochloride (extinction coefficient: 186,970 M−1 cm−1). 
The column resins, SP-Sepharose and Q-Sepharose, were purchased from Amersham Pharmacia and Affi-Gel 
heparin was purchased from Bio-Rad. 
For overproduction of RFC protein complex, pLANT-2/RIL–RFC[1s+5] (or pLANT-2/RIL–RFC[1+5HK]) was 
cotransformed with pET(11a)-RFC[2+3+4] into BLR(DE3) cells as described above. The proteins were 
overexpressed in E. coli as described above for Msh2–Msh6 (12 liters E. coli cell culture). The cells were lysed 
similarly except Buffer C (30 mM Hepes–NaOH (pH 7.5), 0.5 mM EDTA, 7% glycerol) was used and 100 mM NaCl 
was included. RFC was purified by chromatography over a SP-Sepharose column (25 ml bed volume; 250 ml 
gradient of 150–400 mM NaCl in Buffer C) and a Q-Sepharose column (8 ml bed volume; 80 ml gradient of 150–
600 mM NaCl in Buffer C). The purified protein was dialyzed against Buffer C containing 100 mM NaCl. The final 
yields are greater than 5 mg RFC per liter of cell culture greater than 95% pure protein was obtained for each of 
these RFC preparations. Protein concentration was measured by Bradford assay and by absorbance at 280 nm in 
6 M guanidinium hydrochloride (extinction coefficients: RFCHK5 complex: 163,520 M−1cm−1; RFC1s complex, 
162,120 M−1 cm−1). 
Solubility tests of Msh2–Msh6 mismatch repair and RFC clamp loader proteins 
To test the solubility of Msh2, Msh6, and the Msh2–Msh6 complex, the proteins were induced in 100 ml E. 
coli cell cultures (grown from freshly transformed colonies selected for the appropriate plasmids). Cells were 
harvested and lysed as described above in Buffer A containing either 0 or 1 M NaCl. The cell lysate was clarified 
by centrifugation and equivalent amounts (relative to the initial lysate volume) of cleared lysate (soluble 
protein) and cell debris pellet (insoluble protein) were analyzed by 10% SDS–PAGE. Proteins were visualized by 
Coomassie blue staining to assess the relative level of soluble versus insoluble recombinant protein. RFC 
complexes were analyzed similarly (except that cell lysis was performed in Buffer C). RFC subunits were resolved 
by analysis on an 18 cm × 20 cm × 1 mm, 7.5% acrylamide, 0.25% bisacrylamide, 0.1% SDS gel, cross-linked with 
0.16% TEMED (with a 4% stacking gel). The gel was first chilled and then developed at 4 °C at 25 mA constant 
current until the dye front traversed 3/4 of the stacking gel and then at 50 mA until the dye front had entered 
the resolving gel by approximately 3 cm. Following this, the gel was developed at a constant voltage of 300 V 
until the dye was near the end of the gel [19]. The entire process required about 5 h. This is necessary to resolve 
the RFC2, 3, and 5 subunits which otherwise comigrate. 
Activity assays of Msh2–Msh6 mismatch repair and RFC clamp loader proteins 
The mismatch recognition and ATP binding activities of Msh2–Msh6 complex were assayed 
by nitrocellulose membrane binding assays. Briefly, nitrocellulose membranes (0.2 μm pore size; Schleicher & 
Schuell) were pretreated with 0.5 N NaOH, rinsed well with H2O, and equilibrated in Buffer D (50 mM Tris–HCl 
(pH 8), 5 mM MgCl2, 5% glycerol, 110 mM NaCl). Msh2–Msh6 (0–2 μM) was titrated into 15-μl reactions 
containing 32P-labeled 37-nucleotide duplex DNA (0.5 μM), either fully matched or containing a G:T mismatch at 
the center, in Buffer D and 110 mM NaCl (final concentration) at 25 °C. Aliquots of 10 μl were filtered through 
the membrane on a single filter assembly (VWR) under vacuum. The membranes were washed before and after 
filtration with 150 μl Buffer D. The molar amount of DNA bound to Msh2–Msh6 was determined by quantitating 
the radioactivity on the membrane with a PhosphorImager (Molecular Dynamics) and plotted versus Msh2–
Msh6 concentration. 
The concentration of active sites within the Msh2–Msh6 heterodimer was assayed by determining 
the stoichiometry of ATPγS binding to the protein complex. Reactions (15 μl) containing Msh2–Msh6 (1 μM) and 
0–150 μM ATPγS + 0.3 μCi 35S-ATPγS were incubated for 15 min at 25 °C, and 10-μl aliquots were filtered 
through nitrocellulose membranes as described above. The molar amount of nucleotide bound to Msh2–
Msh6 was determined and plotted versus free nucleotide concentration. The binding isotherms were fit to an 
equation describing 1:2 protein–ligand interaction: [N·M]/[Mt]=K1[Nf]+2K1K2[Nf]2/(1+K1[Nf]+2K1K2[Nf]2), 
where N·M is the amount of nucleotide bound to Msh2–Msh6, Mt is total Msh2–Msh6 concentration, Nf is free 
nucleotide concentration, and K1 and K2 are apparent association constants. 
The clamp loading activity of RFC was measured by quantitating PCNA loading onto circular DNA using 32P-
labeled PCNA [20]. PCNAPK (2 μM), a derivative of PCNA containing an N-terminal kinase recognition site [21], 
was phosphorylated in a 100-μl reaction using 50 units of cAMP-dependent protein kinase (New England 
Biolabs) and 20 μCi [γ-32P]ATP in kinase buffer (50 mM Tris–HCl (pH 7.5), 10 mM MgCl2) for 1 h at 37 °C 
(RFCHK5 complex was 32P-labeled in similar fashion). Excess [γ-32P]ATP was removed by filtration through 
Centricon-10 (Millipore) [22]. For the loading reaction, 5.5 nM [32P]PCNA (trimer) was mixed with 8.5 nM 
M13mp18 ssDNA (primed with a 30-mer DNA oligonucleotide), 15 μg SSB, and 1 mM ATP in 100 μl Buffer E 
(30 mM Tris–HCl (pH 7.5), 8 mM MgCl2, 5% glycerol, 0.1 mg/ml bovine serum albumin, 1 mM dithiothreitol, 
0.1 mM EDTA containing 15 mM NaCl). The reaction was initiated with 4.2 nM RFC, incubated at 30 °C for 10 
min, and then filtered over a 5-ml Bio-Gel A-15m column equilibrated in Buffer E containing 100 mM NaCl. 
Fractions of 200 μl were collected and [32P]PCNA was quantitated by scintillation counting. 
Active-site concentration of RFC was assayed by measuring the stoichiometry of DNA binding to the protein 
complex [20]. DNA binding reactions (15 μl) contained 0.5 μM 32P-primed DNA (30-mer primer annealed to a 
DNA 81-mer template) and 0–2 μM RFC in Buffer F (30 mM Hepes–NaOH (pH 7.5), 4 mM MgCl2, 5% glycerol) and 
were incubated for 10 min at 25 °C. Aliquots of 10 μl were filtered through nitrocellulose membranes (which 
were washed before and after filtration with 120 μl Buffer F). The molar amount of 32P-DNA bound to RFC was 
quantitated and analyzed as above. 
Results 
Overexpression of eukaryotic protein complexes in E. coli 
The pET overexpression system is an extremely powerful and popular method for large-scale production of 
bacterial and archaeal proteins, in addition to eukaryotic proteins in E. coli. However, problems with 
poor protein expression and solubility have limited its use in the production of large, multiprotein complexes—
particularly from eukaryotic organisms. Codon bias is an important reason for poor eukaryotic/heterologous 
protein expression in E. coli. For example, genes encoding many S. cerevisiae proteins contain AGA and AGG 
(arginine), CUA (leucine), or AUA (isoleucine) codons that are rarely used in E. coli, and the correspondingly low 
levels of tRNAs are thought to limit translation of these proteins in E. coli[7]. In addition, poor protein solubility 
is especially common with components of multiprotein complexes, likely because the proteins 
misfold/aggregate when produced in the absence of their interacting partners [23]. One way to overcome these 
problems is to co-produce the rare tRNAs and the interacting protein partners of a complex in E. coli. This can be 
achieved by incorporating genes for the rare tRNAs, and for subunits of a multiprotein complex, into a single 
plasmid. However, given the typically large size of eukaryotic protein complexes, such plasmids can be unduly 
difficult to prepare and manipulate. It would be simpler to incorporate the genes into multiple plasmids that can 
be maintained stably within the same cell. To this end, we have developed plasmid vectors that are compatible 
with the pET vector system for simultaneous production of rare tRNAs and several different proteins in E. coli. As 
demonstrated here for S. cerevisiae DNA metabolic proteins, Msh2–Msh6 and five-subunit RFC, milligram 
quantities of active eukaryotic protein complexes from E. coli can be obtained relatively simply with this 
approach. 
Maintenance of two different plasmids in the same cell requires that they have distinct and 
compatible replication origins, as competition between plasmids containing the same origin during replication 
and segregation results in plasmid loss [18]. In addition, the two plasmids must have different antibiotic 
resistance genes for selection of cells containing both plasmids. Thus, a pET-compatible vector was prepared 
with a p15A origin of replication (ColE1 replication origin compatible) and a kanamycin resistance gene. This 
vector was named pLANT to reflect the general compatibility between plants and pets in contrast to two pets 
which may fight (Fig. 1). The pLANT-2 vector diagrammed in Fig. 1 contains a T7 expression unit with a T7 
promoter, ribosome binding sequence, T7 terminator, and multiple restriction site sequence for gene insertion 
derived from pET(11a) or pET(16b). The pLANT-3 vector (not shown) is similar to pLANT-2, except that it contains 
the pET(16b)-derived T7 expression unit, which allows production of His-tagged target proteins. In addition, 
genes encoding rare tRNAs for arginine, isoleucine, and leucine (termed “RIL”) were incorporated into pLANT 
(forming pLANT-2/RIL (Fig. 1) or pLANT-3/RIL) to facilitate overexpression of heterologous proteins in E. coli. 
 
Fig. 1. Schematic of pLANT vector construction. (A) The pLANT-2 vector is derived from pET-9c (KanR) by 
replacement of the ColE1 replication origin with the p15A origin from pACYC184. The pLANT-2 vector also 
incorporates a T7 expression unit derived from pET-11a. This region is expanded in the figure to illustrate the 
sites within it and the initiating codon (boldface). (B) The pLANT-2/RIL vector includes genes encoding tRNAs for 
rare arginine, isoleucine, and leucine codons (denoted as RIL in the figure). 
S. cerevisiae Msh2–Msh6 mismatch repair protein was chosen to test the pLANT+pET system for large-scale 
production of eukaryotic protein complexes in E. coli. Msh2 and Msh6 form a 1:1, 248-kDa heterodimer that 
recognizes basepair mismatches and small insertion/deletion loops in DNA and initiates postreplication DNA 
mismatch repair [24]. These proteins have been purified previously from S. cerevisiae, but in very low quantities, 
and co-expression of Msh2 and Msh6 is necessary because Msh6 is insoluble when overproduced 
alone [6], [25] (although Msh2 appears to be partially soluble). Msh2 and Msh6 genes were inserted into 
the NdeI/BamHI sites of pET-11a and pLANT-2/RIL vectors, respectively, and coexpressed in E. coli BLR(DE3) cells 
(Fig. 2). Both proteins are overproduced in E. coli and Fig. 2A shows that Msh2 is expressed in similar quantities 
from the low-copy pLANT plasmid or the high-copy pET plasmid. Fig. 2B shows that individual expression of the 
proteins yields partially soluble Msh2 but insoluble Msh6 protein. Combined expression of Msh2 and Msh6, 
using pET(11a)–Msh2+pLANT-2/RIL–Msh6 results in an apparent Msh2–Msh6 complex in the soluble fraction of 
the cell lysate (Fig. 2B). To determine whether soluble Msh2–Msh6 complex is produced, the cell lysate was 
fractionated over three different ion-exchange columns. Fig. 2C shows the three-
column chromatography purification profile of Msh2–Msh6, which yields approximately 1 mg of >95% pure 
protein complex per liter of E. coli cells. 
 
Fig. 2. Overproduction of S. cerevisiae Msh2–Msh6 complex in E. coli. (A) The two expression plasmid used to 
produce Msh2–Msh6 complex in E. coli. (B) S. cerevisiae DNA mismatch repair proteins Msh2 (pLANT-2/RIL–
Msh2 and pET(11a)–Msh) and Msh6 (pLANT-2/RIL-Msh6) were expressed individually or together in E. coli and 
tested for solubility, as described under Materials and methods. The SDS–PAGE analysis of Msh2 expression 
demonstrates that similar levels of protein are produced using either the pET or pLANT vector; U, uninduced cell 
extract, I, induced cell extract. (C) The solubility profile of Msh2 (partially soluble), Msh6 (insoluble), and Msh2–
Msh6 (partially soluble); P, pellet from cell lysate; S, supernatant from cell lysate. (D) A purification profile 
for Msh2–Msh6 complex: lane 1, uninduced cell extract; lane 2, induced cell extract; lane 3, cleared cell lysate; 
lane 4, SP-Sepharose eluate; lane 5, heparin eluate; and lane 6, Q-Sepharose eluate. 
The general utility and flexibility of this approach to eukaryotic protein complex production was tested with 
another multiprotein complex, the five-subunit S. cerevisiae replication factor C. RFC is a critical component of 
the DNA replication and repair machinery, as it is responsible for loading circular PCNA clamps at primed DNA 
sites for processive DNA synthesis [26]. Five proteins, RFC1, 2, 3, 4, and 5 together form the 250-kDa RFC clamp 
loader (RFC1, 95 kDa; RFC2, 40 kDa; RFC3, 38 kDa; RFC4, 36 kDa; RFC5, 40 kDa) [27]. These proteins are largely 
insoluble when expressed individually in E. coli or in S. cerevisiae (Fig. 3A); however, co-expression of all five 
genes yields soluble RFC complex (Fig. 3B) [19], [28]. The genes encoding RFC2, 3, and 4 proteins were cloned 
into pET-11a, and genes encoding RFC1 and 5 proteins were placed into the pLANT-2/RIL plasmid containing the 
rare tRNAs for arginine, isoleucine, and leucine. In the example shown here we use a truncated version of RFC1 
(RFC1s) in which the N-terminal 282 amino acids that appear nonessential for DNA replication activity and cell 
viability are deleted [19]. This RFC complex has been expressed previously in E. coli using a single plasmid and 
has been demonstrated to retain clamp-loading activity [19]. Indeed, studies in the human system show that the 
corresponding deletion in human RFC1 leads to fivefold greater activity compared to wild-type RFC [29]. Using 
this pLANT+pET expression system, the five RFC subunits appear in both the soluble and the pellet fractions 
after cell lysis (Fig. 3C). The smaller subunits (RFC2-5) are expressed in stoichiometric excess over the RFC1; the 
reason for this is not clear. The fact that the excess small RFC subunits remain soluble is likely based in the fact 
that they form subassemblies such as RFC34, RFC234, and RFC2345 complex (unpublished). During purification 
of RFC complex, these subassemblies are well separated from RFC. We obtain approximately 5 mg of 95% 
pure S. cerevisiae RFC1s protein from 1 liter of induced cells (Fig. 3D). This amount is approximately five times the 
amount of truncated RFC complex reported earlier, which was obtained using a pET plasmid containing all five 
genes [19]. Our results indicate that use of the low-copy number pLANT plasmid for RFC[1s+5] expression does 
not reduce protein synthesis compared to use of pET plasmid, as illustrated above for Msh2. Moreover, the 
smaller the plasmid (e.g., containing only one or two genes), the simpler it is to introduce specific changes or 
mutations, thereby facilitating the production of multiprotein complexes with only one subunit modified. For 
example, the RFC5 gene was easily modified with an N-terminal tag containing a kinase site and 
multiple histidine residues and combined with the RFC1 gene. This allowed production of RFC containing RFC-5 
with a tag (RFCHK5 complex), which could be labeled with 32P (Fig. 3D). Hence, the pLANT+pET vector system 
facilitates production of mutant multiprotein complexes. 
 
Fig. 3. Overproduction of S. cerevisiae RFC complex in E. coli. (A) The two expression plasmids used to produce 
RFC. (B) When expressed individually, the subunits of replication factor C complex are insoluble. (C) Expression 
and solubility of RFC complex from pLANT-2/RIL-RFC[1s+5] + pET(11a)-RFC[2+3+4]. (D) Purified RFC complex (full-
length) and RFC1s complex (truncated RFC1) with all five subunits resolved. (E) RFCHK5 complex stained with 
Coommassie blue (lane 1) and an autoradiogram of the gel demonstrating that the RFC5HK subunit can be labeled 
with 32P (lane 2). 
S. cerevisiae Msh2–Msh6 and RFC complexes purified from E. coli are fully active 
Next, we tested Msh2–Msh6 and RFC1s complex for activity to determine whether this strategy for eukaryotic 
multiprotein complex production yields biologically active protein complexes. The Msh2–Msh6 complex 
recognizes basepair mismatches in DNA and is known to bind duplex DNA containing a G:T mismatch with high 
affinity relative to fully matched DNA [30]. Fig. 4A shows a titration of 32P-labeled 37-nucleotide duplex DNA 
with increasing concentrations of Msh2–Msh6, assayed by nitrocellulose membrane filtration. Msh2–Msh6 binds 
G:T DNA with high affinity (apparent Kd=38 nM, from experiments performed at lower DNA concentration). 
Further, saturation is reached at a 1:1 stoichiometric ratio of G:T DNA to Msh2–Msh6 complex (0.32 μM 
DNA:0.34 μM Msh2–Msh6). In contrast, there is very little interaction between Msh2–Msh6 and fully matched 
G:C DNA. The active-site concentration of Msh2–Msh6 was measured by ATP binding assays (ATPγS was used as 
a nonhydrolyzable ATP analog). Both Msh2 and Msh6 contain Walker A (ATP binding) and B (Mg2+ binding) 
motifs, suggesting that the Msh2 Msh6 complex binds two molecules of ATP. As illustrated in Fig. 4B, titration 
of Msh2–Msh6 (1 μM) with increasing concentrations of ATPγS yields a stoichiometry of approximately 2 ATPγS 
molecules bound to the Msh2–Msh6 heterodimer. The two ATPγS molecules bind Msh2–Msh6 with differing 
affinities (apparent Kd=4 and 20 μM), consistent with reports of asymmetry in Msh2 and Msh6 function [31]. 
Thus, the S. cerevisiae Msh2–Msh6 complex purified from E. coli appears to be fully active with respect 
to nucleotide binding and mismatch recognition. 
 
Fig. 4. Activity of S. cerevisiae Msh2–Msh6 and RFC complexes produced in E. coli. (A) Msh2–Msh6 binds with 
high affinity to duplex DNA containing a G:T mismatch while binding to matched G:C DNA is nearly undetectable, 
as measured by nitrocellulose membrane assays. (B) Active-site concentration of Msh2–Msh6 was determined 
by measuring the stoichiometry of ATPγS binding to Msh2–Msh6 (both proteins have Walker ATP-binding 
motifs). Two ATPγS molecules bind per Msh2–Msh6, indicating that the recombinant protein complex is fully 
active (Kd=4 and 20 μM for the two binding sites). (C) Clamp loading activity of RFC1s complex assayed by 
assembly of 32P-labeled PCNA onto circular, primed M13mp18 single-stranded DNA. (D) The active-site 
concentration of RFC1s, determined by measuring the stoichiometry of primer–template DNA binding to RFC by 
nitrocellulose membrane assays. RFC1s binds DNA with near 1:1 stoichiometry, indicating that the recombinant 
protein is >95% active. 
To determine whether the recombinant RFC complex is active, we tested the ability of truncated RFC1s complex 
to load 32P-labeled PCNA onto a large circular M13mp18 ssDNA primed with a single oligonucleotide (Fig. 4C). 
Assembly of 32P-PCNA onto the DNA is monitored by analysis of the reaction on a large pore gel filtration resin 
such as BioGel A-15m. In this analysis, the topologically linked 32P-PCNA–DNA complex is large compared to 32P-
PCNA alone and elutes early from the column (fractions 7-12), while free 32P-PCNA elutes later (fractions 14–25). 
No PCNA assembly occurs in the absence of ATP (Fig. 4C). The stoichiometry of RFC1s binding to DNA was 
measured by nitrocellulose membrane binding assays in which 0.5 μM 32P-labeled primer–template DNA (31/81 
nucleotides) was mixed with increasing concentrations of RFC1s. Fig. 4D shows that the binding isotherm reaches 
saturation near a 1:1 ratio of DNA:RFC1s (0.49:0.51, DNA:RFC1s), indicating that the complex is >95% active for 
binding the DNA substrate. 
Discussion 
Eukaryotic proteins are generally less well characterized than their prokaryotic counterparts, especially with 
respect to analysis of structure and detailed mechanism of action. One important contributing factor is the high-
milligram quantity of protein required for crystallographic or kinetic studies, and the difficulty in producing such 
large amounts of protein, especially multicomponent protein complexes, in eukaryotic organisms. E. coli is used 
widely as a host organism to overproduce bacterial proteins because it is easy and inexpensive to grow, and an 
in-depth understanding of this organism has led to development of many useful strains and cloning vectors. In 
recent years, a growing list of examples suggests that E. coli may be just as useful for eukaryotic/heterologous 
protein production [9], [15]. Several of the problems associated with eukaryotic protein production in E. coli are 
now being addressed successfully. For example, heterologous proteins produced in high amounts tend to 
misfold and aggregate, but their solubility can be enhanced by coexpression of molecular chaperones [32]. In 
the case of multiprotein complexes, coexpression of interacting protein partners may be sufficient for proper 
folding and assembly [10], [12], [13]. In another example, differences in codon usage in prokaryotes and 
eukaryotes (which can substantially reduce protein production) can be resolved by replacement of rare codons 
in the genes, but more easily by co-expression of rare tRNA genes in E. coli[16]. Thus, the strategy of co-
expression can be useful in many cases and has been utilized here to enhance production of large, multiprotein 
complexes from S. cerevisiae in E. coli (Fig. 1, Fig. 2). The vectors developed in this study make it easy to co-
express multiple proteins and rare tRNAs in E. coli, and our success with production of two very different protein 
complexes, Msh2–Msh6 and replication factor C, indicate that this strategy is likely to be generally applicable. 
For the Msh2–Msh6 complex, the yields have improved from 0.1–0.2 mg pure protein/g S. 
cerevisiae cells [30] (which are a lot more cumbersome and expensive to grow than E. coli) to 0.5–0.8 mg pure 
protein/g E. coli cells. More importantly, the recombinant protein complex appears to be fully active when 
assayed for mismatch recognition and ATPγS binding activity (Fig. 4). The steady state ATPase activity of E. coli-
produced Msh2–Msh6 is also consistent with earlier reports [31] (kcat=0.5 s−1 at 30 °C, data not shown). 
For the RFC complex, the yield is approximately 2.5 mg pure protein/g E. coli cells which is a substantial 
improvement over the previously reported yield of 0.02 mg/g S. cerevisiae cells [28] and the more recently 
reported yield of 0.5 mg/g E. coli cells of a truncated version of RFC [19] (In the previous study, the 
truncated RFC1 gene was combined with genes for RFC2, 3, 4, 5 in a single pET-based expression vector and co-
expressed with the rare argU tRNA in E. coli). As observed in the case of Msh2–Msh6, the five-subunit RFC 
complex also appears to be fully active for binding its substrates, DNA and PCNA, and is therefore suitable for 
further crystallographic and kinetic analysis. 
In addition to improving wild-type eukaryotic protein complex production in E. coli, the pLANT+pET coexpression 
system facilitates modification/mutation of specific subunits within the complex. As demonstrated for 
His/kinase-tagged RFCHK5 complex, it is relatively easy to modify one gene in a plasmid containing only two or 
three genes (pLANT-2/RIL–RFC[1+5 ]), rather than in a plasmid containing all five genes. This two-vector strategy 
also facilitates systematic co-expression of various subunit proteins for identification and production of soluble 
sub-complexes, which can be extremely valuable in characterizing the structure and function of multiprotein 
assemblies [33] such as RFC (M. O’Donnell and M.M. Hingorani, unpublished work). 
In summary, a better understanding of protein expression and folding in E. coli and concomitant improvements 
in the tools of recombinant protein production are making E. coli an attractive host for eukaryotic protein 
production, especially for hard-to-purify multicomponent protein complexes. Availability of the Msh2–Msh6 and 
RFC complexes and other proteins produced by the pLANT+pET strategy (e.g., S. cerevisiae MCM proteins [34]) is 
expected to greatly enhance our investigation into the workings of DNA metabolic proteins in eukaryotic 
organisms. We anticipate that this strategy will prove useful for a variety of protein complexes, from S. 
cerevisiae and other eukaryotic organisms as well. 
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